Immunology and Microbiology
Acinetobacter Baumannii
9%
Antifungal Activity
16%
Antimicrobial Activity
15%
Antimicrobial Agent
24%
Antimicrobial Peptides
9%
Biofilm
55%
Blood Plasma
11%
Caenorhabditis elegans
96%
Candida
36%
Candida albicans
92%
Colony Forming Unit S
9%
Colony-Forming Unit
9%
COVID-19
27%
Cryptococcus neoformans
32%
Enterococcus faecalis
15%
Enterococcus faecium
13%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
12%
Filamentation
19%
Galleria mellonella
47%
Hematopoietic Stem Cell Transplantation
11%
Host Immune Response
11%
Human immunodeficiency virus
11%
Hypha
10%
Immune Response
15%
Immunity
12%
Infectious Agent
52%
Influenza
12%
Innate Immune System
13%
Lipid Bilayer
9%
Macrophage
14%
Magnetism
9%
Medline
15%
Methicillin-Resistant Staphylococcus Aureus
55%
Minimum Inhibitory Concentration
23%
Monoclonal Antibody
9%
Mortality Rate
12%
Nematode
29%
Pathogenicity
22%
Penicillium marneffei
13%
Peptoclostridium difficile
13%
Photodynamics
11%
Prevalence
33%
Probiotic
15%
Quorum Sensing
11%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Staphylococcus aureus
56%
Vancomycin-Resistant Enterococcus
16%
Virulence Factor
23%
Virus Nucleocapsid
10%
Wild Type
13%
Pharmacology, Toxicology and Pharmaceutical Science
Antibacterial Activity
9%
Antibiotics
29%
Antifungal Activity
12%
Antifungal Agent
20%
Antifungal Therapy
11%
Antiinfective Agent
66%
Antimicrobial Agent
29%
Antimicrobial Resistance
13%
Biological Marker
9%
Bloodstream Infection
34%
Caenorhabditis elegans
46%
Caffeic Acid Phenethyl Ester
8%
Candida
31%
Candida albicans
33%
Candidemia
17%
Candidiasis
15%
Clinical Trial
20%
Clostridium Difficile Infection
10%
Cohort Study
14%
Comorbidity
11%
Coronavirinae
17%
Diseases
42%
Drug Discovery
19%
Ebola Virus Disease
10%
Enterobacteriaceae
8%
Enterococcus faecium
8%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
14%
Galleria mellonella
15%
Gentamicin
12%
High-Throughput Screening
8%
HIV
21%
Infection
100%
Infectious Agent
21%
Invasive Aspergillosis
10%
Methicillin-Resistant Staphylococcus Aureus
36%
Meticillin
13%
Monoclonal Antibody
9%
Mortality Rate
12%
Mycosis
11%
Nematode
9%
Photodynamic Therapy
9%
Placebo
19%
Prevalence
27%
Randomized Controlled Trial
17%
Remdesivir
11%
SARS Coronavirus
23%
Staphylococcus aureus
56%
Urinary Tract Infection
8%
Vancomycin
10%
Virus Infection
9%
Keyphrases
AIDS/HIV
8%
Amphotericin B
6%
Antifungal Agents
6%
Antifungal Compounds
6%
Antifungal Drug Discovery
6%
Antimicrobial
6%
Antimicrobial Activity
7%
Auranofin
6%
Bacteremia
6%
Bloodstream Infection
13%
C.albicans
7%
Caenorhabditis Elegans
14%
Candida
5%
Candida Albicans (C. albicans)
7%
Candida Colonization
5%
Casirivimab
5%
Clinical Outcomes
6%
Clostridium Difficile Infection
8%
Confidence Interval
58%
COVID-19
23%
Cryptococcal Meningitis
6%
Cumulative Incidence
8%
Dialysis Patients
8%
Embase
7%
Enterococcus Faecalis
8%
Extended-spectrum beta-lactamase-producing Enterobacteriaceae
8%
Galleria Mellonella
9%
Hospitalization
7%
Hospitalized Patients
16%
Imdevimab
5%
Immunomodulatory Effect
5%
Infection Risk
13%
Invasive Aspergillosis
7%
Invertebrate Model
6%
Meta-analysis
68%
Methicillin-resistant Staphylococcus Aureus
11%
Model Host
9%
Odds Ratio
13%
Patients with COVID-19
10%
Pneumonia
7%
PubMed
7%
Retrospective Cohort Study
7%
Risk Factors
7%
Risk Ratio
10%
Solid Organ Transplant Recipients
8%
Staphylococcus Aureus
10%
Staphylococcus Aureus Colonization
8%
Steatotic Liver Disease
5%
Systematic Meta-analysis
41%
Vancomycin-resistant Enterococci
15%